NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx and its university partners will use funding from the UK's Biomedical Catalyst program to develop and integrate the company's lab-on-a-chip technology into a device for rapidly diagnosing and staging cancers.

The company said on Sunday that it and its partners at the University of Newcastle and the University of Sheffield will use the £1.4 million ($2.2 million) in new funding to support development of a low-cost, sample-to-result benchtop device through an effort called the Q-Cancer project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.